

Lars Farde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7801833/publications.pdf>

Version: 2024-02-01

147
papers

11,625
citations

30551

56
h-index

34195

103
g-index

153
all docs

153
docs citations

153
times ranked

8739
citing authors

#	ARTICLE	IF	CITATIONS
1	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	2.2	18
2	Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis. <i>Molecular Psychiatry</i> , 2022, 27, 1233-1240.	4.1	13
3	Decreased 5-HT _{1A} binding in mild Alzheimer's disease—A positron emission tomography study. <i>Synapse</i> , 2022, 76, .	0.6	2
4	Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1776-1778.	2.2	0
5	Synthesis and Preclinical Evaluation of [¹¹ C]AZ11895530 for PET Imaging of the Serotonin 1A Receptor. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2078-2083.	1.7	0
6	Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. <i>Clinical Cancer Research</i> , 2021, 27, 189-201.	3.2	106
7	Low convergent validity of [¹¹ C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [¹¹ C]FLB 457. <i>NeuroImage</i> , 2021, 226, 117523.	2.1	11
8	Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study. <i>Neuro-Oncology</i> , 2021, 23, 687-696.	0.6	35
9	Serotonin transporter availability in adults with autism—a positron emission tomography study. <i>Molecular Psychiatry</i> , 2021, 26, 1647-1658.	4.1	27
10	No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis. <i>NPJ Schizophrenia</i> , 2021, 7, 46.	2.0	3
11	The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans. <i>Neuropharmacology</i> , 2020, 162, 107809.	2.0	10
12	In response to the letter “[¹¹ C]raclopride and extrastriatal binding to D2/3 receptors”. <i>NeuroImage</i> , 2020, 207, 116371.	2.1	2
13	M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS — A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY. <i>Schizophrenia Bulletin</i> , 2020, 46, S135-S136.	2.3	0
14	Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness. <i>Schizophrenia Research</i> , 2020, 222, 175-184.	1.1	2
15	High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2407-2416.	3.3	12
16	Quantification and reliability of [¹¹ C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects. <i>EJNMMI Research</i> , 2020, 10, 59.	1.1	5
17	Kinfitr—An open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. <i>EJNMMI Research</i> , 2020, 10, 77.	1.1	14
18	Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [¹¹ C]PBR28 HRRT PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2329-2338.	3.3	70

#	ARTICLE	IF	CITATIONS
19	Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator. EJNMMI Research, 2019, 9, 9.	1.1	9
20	Validity and reliability of extrastriatal [¹¹ C]raclopride binding quantification in the living human brain. NeuroImage, 2019, 202, 116143.	2.1	36
21	D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients. International Journal of Neuropsychopharmacology, 2019, 22, 415-425.	1.0	25
22	PET imaging of [¹¹ C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 367-375.	3.3	50
23	Potential for imaging the high-affinity state of the 5-HT _{1B} receptor: a comparison of three PET radioligands with differing intrinsic activity. EJNMMI Research, 2019, 9, 100.	1.1	4
24	Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170156.	1.8	24
25	The metabotropic glutamate receptor 5 radioligand [¹¹ C]AZD9272 identifies unique binding sites in primate brain. Neuropharmacology, 2018, 135, 455-463.	2.0	13
26	The MINDVIEW project: First results. European Psychiatry, 2018, 50, 21-27.	0.1	19
27	[¹¹ C]SCH23390 binding to the D1-dopamine receptor in the human brain—a comparison of manual and automated methods for image analysis. EJNMMI Research, 2018, 8, 74.	1.1	9
28	Test-retest reliability and convergent validity of (R)-[¹¹ C]PK11195 outcome measures without arterial input function. EJNMMI Research, 2018, 8, 102.	1.1	21
29	The development of a GPR44 targeting radioligand [¹¹ C]AZ12204657 for in vivo assessment of beta cell mass. EJNMMI Research, 2018, 8, 113.	1.1	15
30	GABA _A receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science Translational Medicine, 2018, 10, .	5.8	41
31	Serotonin concentration enhancers at clinically relevant doses reduce [¹¹ C]AZ10419369 binding to the 5-HT _{1B} receptors in the nonhuman primate brain. Translational Psychiatry, 2018, 8, 132.	2.4	11
32	The immune response of the human brain to abdominal surgery. Annals of Neurology, 2017, 81, 572-582.	2.8	87
33	Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [¹¹ C]SCH-23390. NeuroImage, 2017, 155, 344-353.	2.1	20
34	GABA _A receptor occupancy by subtype selective GABA _A α 2,3 modulators: PET studies in humans. Psychopharmacology, 2017, 234, 707-716.	1.5	21
35	[¹¹ C]AZ10419096—a full antagonist PET radioligand for imaging brain 5-HT _{1B} receptors. Nuclear Medicine and Biology, 2017, 54, 34-40.	0.3	8
36	Characterization of [¹¹ C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 308-320.	3.3	7

#	ARTICLE	IF	CITATIONS
37	Fenfluramine Reduces [¹¹ C]Cimbi-36 Binding to the 5-HT _{2A} Receptor in the Nonhuman Primate Brain. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 683-691.	1.0	25
38	Assessment of simplified ratio-based approaches for quantification of PET [¹¹ C]PBR28 data. <i>EJNMMI Research</i> , 2017, 7, 58.	1.1	33
39	Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [¹⁸ F]FDG-¼PET Study. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 169-180.	1.2	9
40	Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 464-471.	1.3	4
41	In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. <i>Brain, Behavior, and Immunity</i> , 2016, 54, 149-157.	2.0	48
42	Low serotonin _{1B} receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2016, 253, 36-42.	0.9	21
43	Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using ¹⁸ F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1529-1534.	2.8	21
44	Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [¹⁸ F]Lu AF10628. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw023.	1.0	1
45	Discovery and Preclinical Validation of [¹¹ C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. <i>ACS Chemical Neuroscience</i> , 2016, 7, 177-184.	1.7	7
46	A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. <i>Neuropharmacology</i> , 2016, 101, 519-530.	2.0	12
47	¹¹ C-carboxylation reactions using gas-liquid segmented microfluidics. <i>RSC Advances</i> , 2015, 5, 88886-88889.	1.7	19
48	TSPO binding may also represent "resting" microglia. <i>Clinical and Translational Imaging</i> , 2015, 3, 491-492.	1.1	2
49	⁵ HT _{1B} receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients. <i>Synapse</i> , 2015, 69, 365-374.	0.6	19
50	Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. <i>Nuclear Medicine and Biology</i> , 2015, 42, 555-560.	0.3	21
51	Amphetamine Decreases ¹² C-Adrenoceptor Binding of [¹¹ C]ORM-13070: A PET Study in the Primate Brain. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu081-pyu081.	1.0	13
52	Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv036.	1.0	34
53	Synthesis of ([¹¹ C]carbonyl)raclopride and a comparison with ([¹¹ C]methyl)raclopride in a monkey PET study. <i>Nuclear Medicine and Biology</i> , 2015, 42, 893-898.	0.3	18
54	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. <i>Brain</i> , 2015, 138, 2687-2700.	3.7	168

#	ARTICLE	IF	CITATIONS
55	Diurnal and seasonal variation of the brain serotonin system in healthy male subjects. <i>NeuroImage</i> , 2015, 112, 225-231.	2.1	56
56	Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [11C]MADAM PET study. <i>Psychopharmacology</i> , 2015, 232, 4159-4167.	1.5	9
57	Quantitative Analysis of ¹⁸ F-(<i>E</i>)- <i>N</i> -(3-Iodoprop-2-Enyl)-2 ¹² -Carbofluoroethoxy-3 ¹² -(4 ² -Methyl-Phenyl) Nortropine Binding to the Dopamine Transporter in Parkinson Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 714-720.	2.8	46
58	Quantification of Blood Flow-Dependent Component in Estimates of Beta-Amyloid Load Obtained Using Quasi-Steady-State Standardized Uptake Value Ratio. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1485-1493.	2.4	27
59	Application of cross-species PET imaging to assess neurotransmitter release in brain. <i>Psychopharmacology</i> , 2015, 232, 4129-4157.	1.5	61
60	Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. <i>Schizophrenia Research</i> , 2014, 158, 156-162.	1.1	209
61	Test-retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 301-307.	3.3	29
62	Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer 11C-AZD2184. <i>Journal of Nuclear Medicine</i> , 2014, 55, 932-938.	2.8	17
63	Distinct regional age effects on [11C]AZ10419369 binding to 5-HT1B receptors in the human brain. <i>NeuroImage</i> , 2014, 103, 303-308.	2.1	21
64	Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study. <i>NeuroImage</i> , 2014, 102, 590-595.	2.1	37
65	¹⁸ F-MCL-524, an ¹⁸ F-Labeled Dopamine D ₂ and D ₃ Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1164-1170.	2.8	20
66	Reduced 5-HT1B receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2014, 223, 164-170.	0.9	61
67	Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 867-875.	1.5	25
68	Quantification of serotonin transporter availability with [11C]MADAM - A comparison between the ECAT HRRT and HR systems. <i>NeuroImage</i> , 2012, 60, 800-807.	2.1	47
69	Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects. <i>EJNMMI Research</i> , 2012, 2, 15.	1.1	86
70	Dopamine D1 receptors and age differences in brain activation during working memory. <i>Neurobiology of Aging</i> , 2011, 32, 1849-1856.	1.5	103
71	Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. <i>Nuclear Medicine and Biology</i> , 2011, 38, 261-272.	0.3	26
72	Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 97-103.	1.9	154

#	ARTICLE	IF	CITATIONS
73	Quantitative Analysis of [¹¹ C]AZ10419369 Binding to 5-HT _{1B} Receptors in Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 113-123.	2.4	72
74	Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability. <i>NeuroImage</i> , 2010, 50, 323-328.	2.1	44
75	Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1639-1650.	3.3	173
76	[¹⁸ F]Flumazenil binding to central benzodiazepine receptor studies by PET. <i>NeuroImage</i> , 2009, 45, 891-902.	2.1	74
77	[¹¹ C]Cyclopropyl-FLB 457: A PET radioligand for low densities of dopamine D2 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6467-6473.	1.4	7
78	Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. <i>NeuroImage</i> , 2008, 40, 1287-1295.	2.1	65
79	[¹¹ C]AZ10419369: A selective 5-HT _{1B} receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. <i>NeuroImage</i> , 2008, 41, 1075-1085.	2.1	78
80	Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [¹¹ C]MNPA and antagonist [¹¹ C]raclopride. <i>Synapse</i> , 2006, 59, 260-269.	0.6	108
81	Measurement of serotonin transporter binding with PET and [¹¹ C]MADAM: A test-retest reproducibility study. <i>Synapse</i> , 2006, 60, 256-263.	0.6	47
82	Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. <i>Psychiatry Research - Neuroimaging</i> , 2006, 148, 165-173.	0.9	66
83	Synthesis and PET evaluation of (R)-[S-methyl- ¹¹ C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 1007-1019.	0.5	14
84	Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. <i>Brain</i> , 2006, 129, 2017-2028.	3.7	224
85	[¹¹ C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. <i>Synapse</i> , 2005, 58, 173-183.	0.6	56
86	Effect of amphetamine on dopamine D2 receptor binding in the primate brain with the agonist ligand [¹¹ C]MNPA. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S646-S646.	2.4	0
87	Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. <i>NeuroImage</i> , 2004, 22, 794-803.	2.1	92
88	Low Dopamine D2Receptor Binding in Subregions of the Thalamus in Schizophrenia. <i>American Journal of Psychiatry</i> , 2004, 161, 1016-1022.	4.0	115
89	The Serotonin System and Spiritual Experiences. <i>American Journal of Psychiatry</i> , 2003, 160, 1965-1969.	4.0	244
90	Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [¹¹ C]FLB 457. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 361-370.	1.0	110

#	ARTICLE	IF	CITATIONS
91	PET Study of D1 Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2002, 159, 761-767.	4.0	171
92	Decreased Dopamine D2 Receptor Binding in the Anterior Cingulate Cortex in Schizophrenia. <i>Archives of General Psychiatry</i> , 2002, 59, 25.	13.8	173
93	Wavelet-Aided Parametric Mapping of Cerebral Dopamine D2 Receptors Using the High Affinity PET Radioligand [11C]FLB 457. <i>NeuroImage</i> , 2002, 17, 47-60.	2.1	53
94	SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 13-24.	2.2	12
95	Dopamine and cognitive functioning: Brain imaging findings in Huntington's disease and normal aging. <i>Scandinavian Journal of Psychology</i> , 2001, 42, 287-296.	0.8	82
96	Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study. <i>Synapse</i> , 2000, 38, 138-143.	0.6	55
97	Autoradiographic localization of 5-HT _{2A} receptors in the human brain using [3H]M100907 and [11C]M100907. <i>Synapse</i> , 2000, 38, 421-431.	0.6	113
98	Synthesis of [11C]2-(3-(3-iodo-4-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2000, 43, 1033-1046.	0.5	1
99	Radiochemical labelling of the dopamine D3 receptor ligand RGH-1756. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2000, 43, 1069-1074.	0.5	10
100	Age-Related Cognitive Deficits Mediated by Changes in the Striatal Dopamine System. <i>American Journal of Psychiatry</i> , 2000, 157, 635-637.	4.0	383
101	Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. <i>Neurobiology of Aging</i> , 2000, 21, 683-688.	1.5	313
102	Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. <i>International Journal of Neuropsychopharmacology</i> , 1999, 2, 73-82.	1.0	96
103	Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 1164-1173.	2.4	164
104	Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M1 and M2 muscarinic acetylcholine receptors in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1482-1485.	3.3	10
105	Pindolol binding to 5-HT _{1A} receptors in the human brain confirmed with positron emission tomography. <i>Psychopharmacology</i> , 1999, 144, 303-305.	1.5	44
106	A PET study of D ₁ -like dopamine receptor ligand binding. <i>Psychopharmacology</i> , 1999, 146, 220-227.	1.5	63
107	Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with pet in nonhuman primates. , 1999, 31, 154-162.		73
108	Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 941-950.	2.4	144

#	ARTICLE	IF	CITATIONS
109	[carbonyl - 11 C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT 1A receptors in vitro and in vivo. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 338-346.	3.3	54
110	Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 531-534.	3.3	41
111	Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET). European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 1261-1267.	3.3	14
112	In vitro and in vivo characterisation of nor- α -CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 596-601.	2.2	68
113	D2 dopamine receptors and personality traits. Nature, 1997, 385, 590-590.	13.7	198
114	A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects. Neuropsychopharmacology, 1997, 16, 1-7.	2.8	117
115	Iodine-123 labeled nor- α -CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 25, 19-23.	3.3	59
116	Central 5-HT 2A and D 2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology, 1997, 131, 339-345.	1.5	22
117	Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Development Research, 1997, 40, 158-170.	1.4	89
118	Effect of reserpine-induced depletion of synaptic dopamine on [^{11}C]Raclopride binding to D2-dopamine receptors in the monkey brain. , 1997, 25, 321-325.		96
119	Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241). European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 798-803.	2.2	9
120	Positron Emission Tomography of <i>in-vivo</i> Binding Characteristics of Atypical Antipsychotic Drugs. British Journal of Psychiatry, 1996, 168, 40-44.	1.7	81
121	Effects of cocaine on [^{11}C]norepinephrine and [^{11}C] α -CIT uptake in the primate peripheral organs measured by PET. Annals of Nuclear Medicine, 1996, 10, 85-88.	1.2	8
122	Autoradiographic localisation of D 3 -dopamine receptors in the human brain using the selective D 3 -dopamine receptor agonist (+)-[3 H]PD 128907. Psychopharmacology, 1996, 128, 240-247.	1.5	115
123	Characterization of C-11 or I-123 Labelled α -CIT-FP and α -CIT-FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC. Human Psychopharmacology, 1996, 11, 483-490.	0.7	21
124	[^{11}C] α -CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. , 1996, 22, 386-390.		76
125	Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [^{125}I]epidepride. , 1996, 23, 115-123.		148
126	Synthesis of 2 ^{125}I -carbomethoxy-3 ^{125}I -(4-[^{76}Br]bromophenyl)tropane ([^{76}Br] ^{125}I -CBT), a pet tracer for in vivo imaging of the dopamine uptake sites. Journal of Labelled Compounds and Radiopharmaceuticals, 1995, 36, 385-392.	0.5	9

#	ARTICLE	IF	CITATIONS
127	Lipophilic metabolite of [¹²³ I]β-CIT in human plasma may obstruct quantitation of the dopamine transporter. <i>Synapse</i> , 1995, 19, 297-300.	0.6	19
128	Variability in D2-dopamine receptor density and affinity: A PET study with [¹¹ C]raclopride in man. <i>Synapse</i> , 1995, 20, 200-208.	0.6	176
129	Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain. <i>Neuropsychopharmacology</i> , 1994, 11, 245-256.	2.8	366
130	Pet study of [¹¹ C] β-CIT binding to monoamine transporters in the monkey and human brain. <i>Synapse</i> , 1994, 16, 93-103.	0.6	162
131	Metabolism of the PET ligand [¹¹ C]SCH 23390. Identification of two radiolabelled metabolites with HPLC. <i>Human Psychopharmacology</i> , 1994, 9, 25-31.	0.7	56
132	PET examination of [¹¹ C]NNC 687 and [¹¹ C]NNC 756 as new radioligands for the D1-dopamine receptor. <i>Psychopharmacology</i> , 1993, 113, 149-156.	1.5	121
133	Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. <i>Biological Psychiatry</i> , 1993, 33, 227-235.	0.7	482
134	Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine. <i>Archives of General Psychiatry</i> , 1992, 49, 538.	13.8	1,357
135	PET Analysis Indicates Atypical Central Dopamine Receptor Occupancy in Clozapine-Treated Patients. <i>British Journal of Psychiatry</i> , 1992, 160, 30-33.	1.7	94
136	[¹¹ C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. <i>Psychopharmacology</i> , 1992, 108, 16-22.	1.5	44
137	Ligand metabolites in plasma during PET-studies with the ¹¹ C-labelled dopamine antagonists, raclopride, SCH 23390 and N-methylspiperidol. <i>Human Psychopharmacology</i> , 1992, 7, 97-103.	0.7	24
138	¹¹ C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET. <i>Psychopharmacology</i> , 1991, 103, 150-153.	1.5	35
139	Comparison of the In Vitro Receptor Binding Properties of N-[³ H]Methylspiperone and [³ H]Raclopride to Rat and Human Brain Membranes. <i>Journal of Neurochemistry</i> , 1990, 55, 2048-2057.	2.1	98
140	Maps of receptor binding parameters in the human brain ? a kinetic analysis of PET measurements. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1990, 16, 257-265.	2.2	88
141	Saturation analysis of specific ¹¹ C Ro 15-1788 binding to the human neocortex using positron emission tomography. <i>Human Psychopharmacology</i> , 1989, 4, 21-31.	0.7	80
142	Raclopride, a new selective ligand for the dopamine-D2 receptors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1988, 12, 559-568.	2.5	104
143	Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs. <i>Archives of General Psychiatry</i> , 1988, 45, 71.	13.8	661
144	The application of positron emission tomography in psychiatry. <i>Nordic Journal of Psychiatry</i> , 1988, 42, 107-110.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen. <i>Annals of Neurology</i> , 1987, 22, 457-468.	2.8	270
146	Preparation of ¹¹ C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1986, 37, 1039-1043.	0.5	169
147	Imaging of [¹¹ C]-labelled RO 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. <i>Journal of Psychiatric Research</i> , 1985, 19, 609-622.	1.5	171